Serotonin transporter immunoreactivity is modulated during development and after fluoxetine treatment in the rodent visual system

Neurosci Lett. 2017 Sep 14:657:38-44. doi: 10.1016/j.neulet.2017.07.047. Epub 2017 Jul 26.

Abstract

The serotonin transporter (5-HTT) regulates serotonin homeostasis and has been used as a target for different drugs in depression treatment. Although the serotonergic system has received a lot of attention, little is known about the effects of these drugs over serotonin transporters. In this work, we investigated the expression pattern of 5-HTT during development of the visual system and the influence of fluoxetine on different signaling pathways. Our data showed that the expression of 5-HTT has a gradual increase from postnatal day 0 until 42 and decrease afterwards. Moreover, chronic fluoxetine treatment both in childhood and adolescence induces down regulation of 5-HTT expression and phosphorylation of ERK and AKT signaling pathways. Together these data suggest that the levels of 5-HTT protein could be important for the development of the central nervous system and suggest that the ERK and AKT are involved in the molecular pathways of antidepressants drugs, acting in concert to improve serotonergic signaling.

Keywords: Fluoxetine; Plasticity; Serotonin transporter; Visual system development.

MeSH terms

  • Animals
  • Animals, Newborn
  • Fluoxetine / administration & dosage
  • Fluoxetine / pharmacology*
  • Humans
  • MAP Kinase Signaling System / drug effects
  • Neuronal Plasticity / drug effects*
  • Proto-Oncogene Proteins c-akt / drug effects*
  • Rats
  • Selective Serotonin Reuptake Inhibitors / administration & dosage
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Serotonin Plasma Membrane Transport Proteins / drug effects*
  • Signal Transduction / drug effects*
  • Superior Colliculi / drug effects*

Substances

  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin Uptake Inhibitors
  • Fluoxetine
  • Proto-Oncogene Proteins c-akt